Shukho Kim

Prof. Dr. Shukho Kim

Kyungpook National University, School of Medicine, Daegu, Republic of Korea
orcid

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2020 in Journal of Global Antimicrobial Resistance
Verified
Journal Article
Open access
SKShukho Kim
Shukho Kim
DLDa-Won Lee
Da-Won Lee
JJJong-Sook Jin
Jong-Sook Jin
JKJung Min Kim
Jung Min Kim
Multidrug-resistant (MDR) bacteria are a major concern in public health. Endolysins (lysins) from bacteriophage can be used as a novel antimicrobial agent against bacterial infectious diseases. In this study, a novel endolysin (LysSS) containing a lysozyme-like domain was evaluated for its antibacterial activity against various bacterial species. LysSS-encoding gene was analyzed and cloned and LysSS recombinant protein was expressed and purified. Purified LysSS was used to determine antimicrobial activities against various bacterial speciesin vitro and to measure its protection rate against Acinetobacter baumannii systemic infection model in vivo. Recombinant LysSS showed activity against MDRAcinetobacter baumannii, MDR Escherichia coli, MDR Klebsiella pneumoniae, MDR Pseudomonas aeruginosa, and Salmonella without pretreatment with an outer membrane permeabilizer. Moreover, LysSS inhibited the growth of methicillin-resistant Staphylococcus aureus (MRSA). The minimum inhibitory concentration of LysSS against 16 strains of MDR Acinetobacter baumannii ranged from 0.063 to 0.25 mg/mL. LysSS had no cytotoxic effect on A549 human lung cells under 250 µg/mL. In an animal model, mice infected with A. baumannii were protected with a 40% survival rate by intraperitoneal injection of LysSS. Our current results demonstrated that LysSS can be a novel and promising antimicrobial agent against MRSA and MDR Gram-negative bacteria includingA. baumannii and P. aeruginosa.

23 November 2020 in Viruses
Verified
Journal Article
Open access
PDF file
SKShukho Kim
Shukho Kim
JJJong-Sook Jin
Jong-Sook Jin
YCYOON-JUNG CHOI
YOON-JUNG CHOI
JKJung Min Kim
Jung Min Kim
Multidrug-resistant (MDR) bacteria are a major threat to public health. Bacteriophage endolysins (lysins) are a promising alternative treatment to traditional antibiotics. However, the lysins currently under development are still underestimated. Herein, we cloned the lysin from the SAP-26 bacteriophage genome. The recombinant LysSAP26 protein inhibited the growth of carbapenem-resistant Acinetobacter baumannii, Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa, oxacillin-resistant Staphylococcus aureus, and vancomycin-resistant Enterococcus faecium with minimum inhibitory concentrations of 5~80 µg/mL. In animal experiments, mice infected with A. baumannii were protected by LysSAP26, with a 40% survival rate. Transmission electron microscopy analysis confirmed that LysSAP26 treatment resulted in the destruction of bacterial cell walls. LysSAP26 is a new endolysin that can be applied to treat MDR A. baumannii, E. faecium, S. aureus, K. pneumoniae, P. aeruginosa, and E. coli infections, targeting both Gram-positive and Gram-negative bacteria.

1 January 2010 in Journal of Korean Medical Science
Verified
Journal Article
Open access
PDF file
SKShukho Kim
Shukho Kim
Kim S. J Korean Med Sci. 2010 Dec;25(12):1693-1699. http://dx.doi.org/10.3346/jkms.2010.25.12.1693

22 July 2024 in Antibiotics
Verified
Journal Article
Open access
PDF file
YCYoon-Jung Choi
Yoon-Jung Choi
SKShukho Kim
Shukho Kim
MSMinsang Shin
Minsang Shin
JKJung Min Kim
Jung Min Kim
Acinetobacter baumannii is a challenging multidrug-resistant pathogen in healthcare. Phage vB_AbaSi_W9 (GenBank: PP146379.1), identified in our previous study, shows lytic activity against 26 (89.66%) of 29 carbapenem-resistant Acinetobacter baumannii (CRAB) strains with various sequence types (STs). It is a promising candidate for CRAB treatment; however, its lytic efficiency is insufficient for complete bacterial lysis. Therefore, this study aimed to investigate the clinical utility of the phage vB_AbaSi_W9 by identifying antimicrobial agents that show synergistic effects when combined with it. The A. baumannii ATCC17978 strain was used as the host for the phage vB_AbaSi_W9. Adsorption and one-step growth assays of the phage vB_AbaSi_W9 were performed at MOIs of 0.001 and 0.01, respectively. Four clinical strains of CRAB belonging to different sequence types, KBN10P04948 (ST191), LIS2013230 (ST208), KBN10P05982 (ST369), and KBN10P05231 (ST451), were used to investigate phage–antibiotic synergy. Five antibiotics were tested at the following concentration: meropenem (0.25–512 µg/mL); colistin, tigecycline, and rifampicin (0.25–256 µg/mL); and ampicillin/sulbactam (0.25/0.125–512/256 µg/mL). The in vitro synergistic effect of the phage and rifampicin was verified through an in vivo mouse infection model. Phage vB_AbaSi_W9 demonstrated 90% adsorption to host cells in 1 min, a 20 min latent period, and a burst size of 114 PFU/cell. Experiments combining phage vB_AbaSi_W9 with antibiotics demonstrated a pronounced synergistic effect against clinical strains when used with tigecycline and rifampicin. In a mouse model infected with CRAB KBN10P04948 (ST191), the group treated with rifampicin (100 μg/mL) and phage vB_AbaSi_W9 (MOI 1) achieved a 100% survival rate—a significant improvement over the phage-only treatment (8.3% survival rate) or antibiotic-only treatment (25% survival rate) groups. The bacteriophage vB_AbaSi_W9 demonstrated excellent synergy against CRAB strains when combined with tigecycline and rifampicin, suggesting potential candidates for phage–antibiotic combination therapy in treating CRAB infections.

29 June 2024 in Antibiotics
Verified
Journal Article
Open access
PDF file
YCYoon-Jung Choi
Yoon-Jung Choi
SKShukho Kim
Shukho Kim
MSMinsang Shin
Minsang Shin
JKJung Min Kim
Jung Min Kim
The spread of multidrug-resistant Acinetobacter baumannii in hospitals and nursing homes poses serious healthcare challenges. Therefore, we aimed to isolate and characterize lytic bacteriophages targeting carbapenem-resistant Acinetobacter baumannii (CRAB). Of the 21 isolated A. baumannii phages, 11 exhibited potent lytic activities against clinical isolates of CRAB. Based on host spectrum and RAPD-PCR results, 11 phages were categorized into four groups. Three phages (vB_AbaP_W8, vB_AbaSi_W9, and vB_AbaSt_W16) were further characterized owing to their antibacterial efficacy, morphology, and whole-genome sequence and were found to lyse 37.93%, 89.66%, and 37.93%, respectively, of the 29 tested CRAB isolates. The lytic spectrum of phages varied depending on the multilocus sequence type (MLST) of the CRAB isolates. The three phages contained linear double-stranded DNA genomes, with sizes of 41,326–166,741 bp and GC contents of 34.4–35.6%. Genome-wide phylogenetic analysis and single gene-based tree construction revealed no correlation among the three phages. Moreover, no genes were associated with lysogeny, antibiotic resistance, or bacterial toxins. Therefore, the three novel phages represent potential candidates for phage therapy against CRAB infections.

2 August 2022 in Antibiotics
Verified
Journal Article
Open access
PDF file
SKShukho Kim
Shukho Kim
HSHyesoon Song
Hyesoon Song
JJJong Sook Jin
Jong Sook Jin
WLWeon Ju Lee
Weon Ju Lee
JKJung Min Kim
Jung Min Kim
Cutibacterium acnes is a pathogen that can cause acne vulgaris, sarcoidosis, endodontic lesions, eye infections, prosthetic joint infections, and prostate cancer. Recently, bacteriophage (phage) therapy has been developed as an alternative to antibiotics. In this study, we attempted to isolate 15 phages specific to C. acnes from 64 clinical samples obtained from patients with acne vulgaris. Furthermore, we sequenced the genomes of these three phages. Bioinformatic analysis revealed that the capsid and tape measure proteins are strongly hydrophobic. To efficiently solubilize the phage particles, we measured the adsorption rate, one-step growth curve, and phage stability using an SMT2 buffer containing Tween 20. Here, we report the genotypic and phenotypic characteristics of the novel C. acnes-specific phages.